MAY 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
CHMP (Committee for Medicinal Products for Human Use- EMA) May 21 Camizestrant – BC ESR1. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the oral selective oestrogen receptor degrader (ngSERD) and complete oestrogen receptor (ER) antagonist., […]